A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
← catalyst calendarNCT05688436 · readout in 1,612 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,178estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-24 | actual | When the study began enrolling |
| Primary completion | 2031-01-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-17 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Interventions
- Drug: Diroximel Fumarate — also filed as VUMERITY, BIIB098
- Biological: Alemtuzumab
- Drug: Fingolimod
- Drug: Glatiramer acetate
- Biological: Interferon beta
- Biological: Natalizumab — also filed as Tysabri, BG00002
- Biological: Ocrelizumab
- Biological: Ofatumumab
- Drug: Ozanimod
- Biological: Peginterferon beta-1a
- Drug: Ponesimod
- Drug: Siponimod
Primary outcome
what the primary-completion date above is the date OFNumber of Major Congenital Malformations (MCMs)
measured Up to 52 weeks postdelivery
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed